Drug
E7386
E7386: highest development phase Phase 1/2, developed by Eisai. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Eisai
Trials
| Drug | Phase | Indication |
|---|---|---|
| E7386 NCT04008797 | Phase 1/2 | Endometrial Neoplasms |
| E7386 NCT04840927 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow E7386 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.